Targets › FKS1
3 programs from 3 companies in 7 trials: 3 Phase 1, 2 Phase 3, 2 Phase 2; Infectious disease, Respiratory, Genitourinary; next expected readout Nov 2026.
Open in Phaseline: the race on FKS1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Basilea Pharmaceutica | fosmanogepix GPI-anchored wall transfer protein 1 inhibitor | IPCS1, HMG1, FKS1 | Phase 3 | Candidemia; Invasive Mold Infections; Healthy Adult Participants; End Stage Renal Disease on Dialysis | Mar 2027 |
| Mundipharma Research | Rezafungin Acetate 1,3-beta-D-glucan synthase inhibitor | FKS1 | Phase 2 | Pneumocystis Pneumonia; Chronic Pulmonary Aspergillosis | Nov 2026 |
| University Hospital, Tours | Caspofungin 1,3-beta-glucan synthase inhibitor | FKS1 | Phase 1 | Pneumocystis Pneumonia | Dec 2026 |
Pneumocystis Pneumonia (2) Candidemia (1) Invasive Mold Infections (1) Healthy Adult Participants (1) End Stage Renal Disease on Dialysis (1) Chronic Pulmonary Aspergillosis (1)
small molecule (3)
Basilea Pharmaceutica (1) University Hospital, Tours (1) Mundipharma Research (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.